Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683718 | 0.78 | AR (0.63) | ARPGR | |
| SCHEMBL19603965 | 0.76 | PGR (0.62) | ARPGR | |
| SCHEMBL20459221 | 0.74 | AR (0.59) | ARPGR | |
| SCHEMBL2856726 | 0.73 | AR (0.91) | ARPGR | |
| SCHEMBL19236106 | 0.71 | AR (1.00) | ARPGR | |
| SCHEMBL3017857 | 0.70 | AR (0.59) | ARPGR | |
| SCHEMBL3017276 | 0.69 | AR (0.61) | ARPGR | |
| SCHEMBL14453286 | 0.68 | AR (0.61) | ARPGR | |
| SCHEMBL1771199 | 0.66 | AR (0.70) | ARPGR | |
| SCHEMBL6678538 | 0.66 | AR (0.57) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117580839-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-20230040245-A1 | FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2023-02-09 | — | — | US | claimed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | claimed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-11446400-B2 | Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-09-20 | — | — | US | claimed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12208141-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-10-24 | — | — | US | disclosed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240181066-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-06-06 | — | — | US | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208141-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | AR 4/4885PGR 79/4885 |
| US-20240181066-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885PGR 28/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | AR 2420/4885PGR 2085/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | AR 1207/4885PGR 450/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | AR 5/4885PGR 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.